A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer
We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encountered during the treatment of metastatic medullary thyroid cancer. Proteinuria is a relatively common side effect of VEGF-targeted treatments and can occasionally result in treatment discontinuation....
Saved in:
Main Authors: | Kathryn Fleming, James McGuinness, David Kipgen, Hilary Glen, Pavlina Spiliopoulou |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Case Reports in Oncological Medicine |
Online Access: | http://dx.doi.org/10.1155/2018/6927639 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Focal Segmental Glomerulosclerosis in Waldenström’s Macroglobulinemia
by: Akshee Batra, et al.
Published: (2020-01-01) -
Interferon Induced Focal Segmental Glomerulosclerosis
by: Yusuf Kayar, et al.
Published: (2016-01-01) -
Collapsing Focal Segmental Glomerulosclerosis in a Patient with Acute Malaria
by: Najamus Sehar, et al.
Published: (2015-01-01) -
Recurrent Focal Segmental Glomerulosclerosis: A Discrete Clinical Entity
by: Elena Torban, et al.
Published: (2012-01-01) -
Collapsing Focal Segmental Glomerulosclerosis in a Patient with Systemic Lupus Erythematosus
by: Hassan Tariq, et al.
Published: (2014-01-01)